Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age.

Polepally AR, Brundage RC, Remmel RP, Leppik IE, Pennell PB, White JR, Ramsay RE, Kistner BM, Birnbaum AK.

Epilepsia. 2018 Aug 12. doi: 10.1111/epi.14519. [Epub ahead of print]

PMID:
30101556
2.

Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.

Alhadab AA, Ahmed MA, Brundage RC.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01781-17. doi: 10.1128/AAC.01781-17. Print 2018 Apr.

PMID:
29358293
3.

Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.

Okour M, Jacobson PA, Ahmed MA, Israni AK, Brundage RC.

J Clin Pharmacol. 2018 May;58(5):628-639. doi: 10.1002/jcph.1064. Epub 2018 Jan 12.

PMID:
29329489
4.

Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients.

Ahmed GF, Bathena SP, Brundage RC, Leppik IE, Conway JM, Schwartz JB, Birnbaum AK.

AAPS J. 2017 Mar;19(2):551-556. doi: 10.1208/s12248-016-0022-z. Epub 2017 Jan 9.

PMID:
28070716
5.

Prospective studies of infectious mononucleosis in university students.

Grimm JM, Schmeling DO, Dunmire SK, Knight JA, Mullan BD, Ed JA, Brundage RC, Hogquist KA, Balfour HH Jr.

Clin Transl Immunology. 2016 Aug 12;5(8):e94. doi: 10.1038/cti.2016.48. eCollection 2016 Aug.

6.

A hierarchical Bayesian approach for combining pharmacokinetic/pharmacodynamic modeling and Phase IIa trial design in orphan drugs: Treating adrenoleukodystrophy with Lorenzo's oil.

Basu C, Ahmed MA, Kartha RV, Brundage RC, Raymond GV, Cloyd JC, Carlin BP.

J Biopharm Stat. 2016;26(6):1025-1039. Epub 2016 Aug 22.

7.

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.

Flora DR, Rettie AE, Brundage RC, Tracy TS.

J Clin Pharmacol. 2017 Mar;57(3):382-393. doi: 10.1002/jcph.813. Epub 2016 Sep 22.

PMID:
27539372
8.

Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study.

Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH Jr.

Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May.

9.

Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Liang S, Brundage RC, Jacobson PA, Blaes A, Kirstein MN.

Br J Clin Pharmacol. 2016 Sep;82(3):773-83. doi: 10.1111/bcp.12989. Epub 2016 Jun 3.

10.

A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.

Ahmed MA, Kartha RV, Brundage RC, Cloyd J, Basu C, Carlin BP, Jones RO, Moser AB, Fatemi A, Raymond GV.

Br J Clin Pharmacol. 2016 Jun;81(6):1058-66. doi: 10.1111/bcp.12897. Epub 2016 Apr 3.

11.

Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.

Sanghavi K, Brundage RC, Miller MB, Schladt DP, Israni AK, Guan W, Oetting WS, Mannon RB, Remmel RP, Matas AJ, Jacobson PA.

Pharmacogenomics J. 2017 Jan;17(1):61-68. doi: 10.1038/tpj.2015.87. Epub 2015 Dec 15.

12.

Pharmacokinetic-Pharmacodynamic Modeling of Intravenous and Oral Topiramate and Its Effect on the Symbol-Digit Modalities Test in Adult Healthy Volunteers.

Lim CN, Birnbaum AK, Brundage RC, Leppik IE, Cloyd JC, Clark A, Marino SE.

J Clin Pharmacol. 2016 Jun;56(6):714-22. doi: 10.1002/jcph.646. Epub 2015 Dec 21.

13.

Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.

Polepally AR, Remmel RP, Brundage RC, Leppik IE, Rarick JO, Ramsay RE, Birnbaum AK.

J Clin Pharmacol. 2015 Oct;55(10):1101-8. doi: 10.1002/jcph.522. Epub 2015 Aug 18.

14.

Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.

Bart G, Lenz S, Straka RJ, Brundage RC.

Drug Alcohol Depend. 2014 Dec 1;145:185-93. doi: 10.1016/j.drugalcdep.2014.10.014. Epub 2014 Oct 24.

15.

Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers.

Ahmed GF, Marino SE, Brundage RC, Pakhomov SV, Leppik IE, Cloyd JC, Clark A, Birnbaum AK.

Br J Clin Pharmacol. 2015 May;79(5):820-30. doi: 10.1111/bcp.12556.

16.

MODEL-BASED LAMOTRIGINE CLEARANCE CHANGES DURING PREGNANCY: CLINICAL IMPLICATION.

Polepally AR, Pennell PB, Brundage RC, Stowe ZN, Newport DJ, Viguera AC, Ritchie JC, Birnbaum AK.

Ann Clin Transl Neurol. 2014 Feb;1(2):99-106.

17.

Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.

Vezina HE, Brundage RC, Balfour HH Jr.

Br J Clin Pharmacol. 2014 Aug;78(2):343-52. doi: 10.1111/bcp.12343.

18.

SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.

Khatri A, Williams BW, Fisher J, Brundage RC, Gurvich VJ, Lis LG, Skubitz KM, Dudek AZ, Greeno EW, Kratzke RA, Lamba JK, Kirstein MN.

Br J Cancer. 2014 Jan 21;110(2):304-12. doi: 10.1038/bjc.2013.738. Epub 2013 Dec 3.

19.

Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.

Salem AH, Fletcher CV, Brundage RC.

Antimicrob Agents Chemother. 2014;58(1):136-43. doi: 10.1128/AAC.01738-13. Epub 2013 Oct 21.

20.

Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.

Clark AM, Kriel RL, Leppik IE, White JR, Henry TR, Brundage RC, Cloyd JC.

Epilepsia. 2013 Jun;54(6):1106-11. doi: 10.1111/epi.12165. Epub 2013 Apr 15.

21.

A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers.

Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC.

Epilepsy Res. 2013 Aug;105(3):362-7. doi: 10.1016/j.eplepsyres.2013.02.018. Epub 2013 Apr 2.

PMID:
23561287
22.

Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers.

Clark AM, Kriel RL, Leppik IE, Marino SE, Mishra U, Brundage RC, Cloyd JC.

Epilepsia. 2013 Jun;54(6):1099-105. doi: 10.1111/epi.12134. Epub 2013 Mar 18.

23.

Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.

Ahmed GF, Brundage RC, Marino SE, Cloyd JC, Leppik IE, Pennell PB, Ramsay RE, Birnbaum AK.

J Clin Pharmacol. 2013 Mar;53(3):276-84. doi: 10.1002/jcph.8. Epub 2013 Feb 13.

24.

Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.

Milán Segovia RC, Domínguez Ramírez AM, Jung Cook H, Magaña Aquino M, Vigna Pérez M, Brundage RC, Romano Moreno S.

J Clin Pharm Ther. 2013 Feb;38(1):56-61. doi: 10.1111/jcpt.12016. Epub 2012 Nov 20.

PMID:
23167603
25.

Validation of tacrolimus equation to predict troughs using genetic and clinical factors.

Passey C, Birnbaum AK, Brundage RC, Schladt DP, Oetting WS, Leduc RE, Israni AK, Guan W, Matas AJ, Jacobson PA.

Pharmacogenomics. 2012 Jul;13(10):1141-7. doi: 10.2217/pgs.12.98.

26.

Population pharmacokinetics of carbamazepine in elderly patients.

Punyawudho B, Ramsay ER, Brundage RC, Macias FM, Collins JF, Birnbaum AK.

Ther Drug Monit. 2012 Apr;34(2):176-81. doi: 10.1097/FTD.0b013e31824d6a4e.

27.

Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder.

Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr.

Clin Transplant. 2012 Sep-Oct;26(5):741-7. doi: 10.1111/j.1399-0012.2012.01608.x. Epub 2012 Mar 4.

28.

Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Marino SE, Birnbaum AK, Leppik IE, Conway JM, Musib LC, Brundage RC, Ramsay RE, Pennell PB, White JR, Gross CR, Rarick JO, Mishra U, Cloyd JC.

Clin Pharmacol Ther. 2012 Mar;91(3):483-8. doi: 10.1038/clpt.2011.251. Epub 2012 Jan 25.

29.

Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics.

D'Argenio DZ, Gastonguay MR, Brundage RC, Miller R, Tannenbaum SJ, Pfister M.

J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):3. doi: 10.1007/s10928-011-9237-x. No abstract available.

PMID:
22219000
30.

Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.

Khatri A, Brundage RC, Hull JM, Williams BW, Yee D, Kirstein MN.

AAPS J. 2012 Mar;14(1):1-9. doi: 10.1208/s12248-011-9308-3. Epub 2011 Nov 19.

31.

Dosing equation for tacrolimus using genetic variants and clinical factors.

Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA.

Br J Clin Pharmacol. 2011 Dec;72(6):948-57. doi: 10.1111/j.1365-2125.2011.04039.x.

32.

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.

Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV.

AIDS. 2011 Jul 31;25(12):1489-96. doi: 10.1097/QAD.0b013e328348fc41.

33.

Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy.

Aliwarga T, Cloyd JC, Goel V, Brundage RC, Marino SE, Leppik IE, Remmel RP.

Ther Drug Monit. 2011 Feb;33(1):56-63. doi: 10.1097/FTD.0b013e3182081089.

PMID:
21233690
34.

Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.

Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN.

Cancer Chemother Pharmacol. 2011 Sep;68(3):721-31. doi: 10.1007/s00280-010-1542-3. Epub 2010 Dec 16.

PMID:
21161529
35.

Defining the future of pharmacometrics: the American Society of Pharmacometrics.

Pfister M, Brundage RC, Gastonguay MR, Miller R, Tannenbaum SJ, D'Argenio DZ.

J Clin Pharmacol. 2010 Sep;50(9 Suppl):158S. doi: 10.1177/0091270010377632. No abstract available.

PMID:
20881230
36.

ACoP: the tools, carpenters, and architects building the discipline of pharmacometrics.

Brundage RC, Pfister M, D'Argenio DZ, Gastonguay MR, Miller R, Tannenbaum SJ.

J Clin Pharmacol. 2010 Sep;50(9 Suppl):7S-8S. doi: 10.1177/0091270010376967. No abstract available.

PMID:
20881212
37.

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.

Kolesar J, Brundage RC, Pomplun M, Alberti D, Holen K, Traynor A, Ivy P, Wilding G.

Cancer Chemother Pharmacol. 2011 Feb;67(2):393-400. doi: 10.1007/s00280-010-1331-z. Epub 2010 May 4.

38.

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease.

Vezina HE, Brundage RC, Nevins TE, Balfour HH Jr.

Clin Pharmacol. 2010;2:1-7. doi: 10.2147/CPAA.S8341. Epub 2009 Dec 22.

39.

Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.

Vezina HE, Balfour HH Jr, Weller DR, Anderson BJ, Brundage RC.

J Clin Pharmacol. 2010 Jul;50(7):734-42. doi: 10.1177/0091270009351884. Epub 2009 Nov 6.

40.

Population pharmacokinetics of albendazole in patients with neurocysticercosis.

Castro N, Márquez-Caraveo C, Brundage RC, González-Esquivel D, Suárez AM, Góngora F, Jara A, Urizar J, Lanao JM, Jung H.

Int J Clin Pharmacol Ther. 2009 Nov;47(11):679-85.

PMID:
19840532
41.

Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.

Ahn JE, Cloyd JC, Brundage RC, Marino SE, Conway JM, Ramsay RE, White JR, Musib LC, Rarick JO, Birnbaum AK, Leppik IE.

Neurology. 2008 Jul 1;71(1):38-43. doi: 10.1212/01.wnl.0000316392.55784.57.

PMID:
18591503
42.

Differential genotype dependent inhibition of CYP2C9 in humans.

Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS.

Drug Metab Dispos. 2008 Jul;36(7):1242-8. doi: 10.1124/dmd.108.020396. Epub 2008 Mar 31.

43.

Population pharmacokinetics of lamotrigine in elderly patients.

Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK.

J Clin Pharmacol. 2008 Apr;48(4):455-63. doi: 10.1177/0091270007313391. Epub 2008 Feb 22.

PMID:
18296554
44.

Impact of censoring data below an arbitrary quantification limit on structural model misspecification.

Byon W, Fletcher CV, Brundage RC.

J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):101-16. Epub 2007 Oct 26.

PMID:
17963024
45.

Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents.

Birnbaum AK, Ahn JE, Brundage RC, Hardie NA, Conway JM, Leppik IE.

Ther Drug Monit. 2007 Oct;29(5):571-5.

PMID:
17898646
46.

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, Spector SA.

Clin Pharmacol Ther. 2008 Feb;83(2):300-6. Epub 2007 Jul 4.

47.

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system.

Kirstein MN, Brundage RC, Moore MM, Williams BW, Hillman LA, Dagit JW, Fisher JE, Marker PH, Kratzke RA, Yee D.

Cancer Chemother Pharmacol. 2008 Feb;61(2):291-9. Epub 2007 Apr 12.

PMID:
17429628
48.

Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.

Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley R, Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

Clin Pharmacol Ther. 2007 Jun;81(6):867-72. Epub 2007 Mar 28.

PMID:
17392728
49.

A virologic pilot study of valacyclovir in infectious mononucleosis.

Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC.

J Clin Virol. 2007 May;39(1):16-21. Epub 2007 Mar 21.

PMID:
17369082
50.

An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

Weller DR, Brundage RC, Balfour HH Jr, Vezina HE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 1;848(2):369-73. Epub 2006 Nov 1.

PMID:
17081812

Supplemental Content

Loading ...
Support Center